Bile Duct Cancer Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4140956
- 125 Pages
- December 2020
- Healthcare
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Bile Duct Cancer Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Bile Duct Cancer Drug market segmented into
Cabozantinib S-malate
Elpamotide
Exatecan Mesylate
LY-2801653
NUC-1031
Others
Based on the end-use, the global Bile Duct Cancer Drug market classified into
Hospital
Clinic
Others
Based on geography, the global Bile Duct Cancer Drug market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Ariad Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Aslan Pharmaceuticals Pte. Ltd.
Bavarian Nordic A/S
Bayer AG
Blueprint Medicines Corporation
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CellAct Pharma GmbH
Cellceutix Corporation
Cellular Biomedicine Group, Inc.
Concordia Healthcare Corp
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL BILE DUCT CANCER DRUG INDUSTRY
2.1 Summary about Bile Duct Cancer Drug Industry
2.2 Bile Duct Cancer Drug Market Trends
2.2.1 Bile Duct Cancer Drug Production & Consumption Trends
2.2.2 Bile Duct Cancer Drug Demand Structure Trends
2.3 Bile Duct Cancer Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Cabozantinib S-malate
4.2.2 Elpamotide
4.2.3 Exatecan Mesylate
4.2.4 LY-2801653
4.2.5 NUC-1031
4.2.6 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Cabozantinib S-malate
5.2.2 Elpamotide
5.2.3 Exatecan Mesylate
5.2.4 LY-2801653
5.2.5 NUC-1031
5.2.6 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Cabozantinib S-malate
6.2.2 Elpamotide
6.2.3 Exatecan Mesylate
6.2.4 LY-2801653
6.2.5 NUC-1031
6.2.6 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Cabozantinib S-malate
7.2.2 Elpamotide
7.2.3 Exatecan Mesylate
7.2.4 LY-2801653
7.2.5 NUC-1031
7.2.6 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Cabozantinib S-malate
8.2.2 Elpamotide
8.2.3 Exatecan Mesylate
8.2.4 LY-2801653
8.2.5 NUC-1031
8.2.6 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Cabozantinib S-malate
9.2.2 Elpamotide
9.2.3 Exatecan Mesylate
9.2.4 LY-2801653
9.2.5 NUC-1031
9.2.6 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Ariad Pharmaceuticals, Inc.
10.1.2 ArQule, Inc.
10.1.3 Array BioPharma Inc.
10.1.4 Arrien Pharmaceuticals, LLC
10.1.5 Aslan Pharmaceuticals Pte. Ltd.
10.1.6 Bavarian Nordic A/S
10.1.7 Bayer AG
10.1.8 Blueprint Medicines Corporation
10.1.9 Boehringer Ingelheim GmbH
10.1.10 Boston Biomedical, Inc.
10.1.11 Bristol-Myers Squibb Company
10.1.12 Celgene Corporation
10.1.13 CellAct Pharma GmbH
10.1.14 Cellceutix Corporation
10.1.15 Cellular Biomedicine Group, Inc.
10.1.16 Concordia Healthcare Corp
10.2 Bile Duct Cancer Drug Sales Date of Major Players (2017-2020e)
10.2.1 Ariad Pharmaceuticals, Inc.
10.2.2 ArQule, Inc.
10.2.3 Array BioPharma Inc.
10.2.4 Arrien Pharmaceuticals, LLC
10.2.5 Aslan Pharmaceuticals Pte. Ltd.
10.2.6 Bavarian Nordic A/S
10.2.7 Bayer AG
10.2.8 Blueprint Medicines Corporation
10.2.9 Boehringer Ingelheim GmbH
10.2.10 Boston Biomedical, Inc.
10.2.11 Bristol-Myers Squibb Company
10.2.12 Celgene Corporation
10.2.13 CellAct Pharma GmbH
10.2.14 Cellceutix Corporation
10.2.15 Cellular Biomedicine Group, Inc.
10.2.16 Concordia Healthcare Corp
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
Table Bile Duct Cancer Drug Product Type Overview
Table Bile Duct Cancer Drug Product Type Market Share List
Table Bile Duct Cancer Drug Product Type of Major Players
Table Brief Introduction of Ariad Pharmaceuticals, Inc.
Table Brief Introduction of ArQule, Inc.
Table Brief Introduction of Array BioPharma Inc.
Table Brief Introduction of Arrien Pharmaceuticals, LLC
Table Brief Introduction of Aslan Pharmaceuticals Pte. Ltd.
Table Brief Introduction of Bavarian Nordic A/S
Table Brief Introduction of Bayer AG
Table Brief Introduction of Blueprint Medicines Corporation
Table Brief Introduction of Boehringer Ingelheim GmbH
Table Brief Introduction of Boston Biomedical, Inc.
Table Brief Introduction of Bristol-Myers Squibb Company
Table Brief Introduction of Celgene Corporation
Table Brief Introduction of CellAct Pharma GmbH
Table Brief Introduction of Cellceutix Corporation
Table Brief Introduction of Cellular Biomedicine Group, Inc.
Table Brief Introduction of Concordia Healthcare Corp
Table Products & Services of Ariad Pharmaceuticals, Inc.
Table Products & Services of ArQule, Inc.
Table Products & Services of Array BioPharma Inc.
Table Products & Services of Arrien Pharmaceuticals, LLC
Table Products & Services of Aslan Pharmaceuticals Pte. Ltd.
Table Products & Services of Bavarian Nordic A/S
Table Products & Services of Bayer AG
Table Products & Services of Blueprint Medicines Corporation
Table Products & Services of Boehringer Ingelheim GmbH
Table Products & Services of Boston Biomedical, Inc.
Table Products & Services of Bristol-Myers Squibb Company
Table Products & Services of Celgene Corporation
Table Products & Services of CellAct Pharma GmbH
Table Products & Services of Cellceutix Corporation
Table Products & Services of Cellular Biomedicine Group, Inc.
Table Products & Services of Concordia Healthcare Corp
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Bile Duct Cancer Drug Market Forecast (Million USD) by Region 2021f-2026f
Table Global Bile Duct Cancer Drug Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Bile Duct Cancer Drug Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Bile Duct Cancer Drug Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
